Variable Interest Entity (Details) $ in Thousands		3 Months Ended								12 Months Ended
	Jun. 30, 2015 USD ($)	Dec. 31, 2016 USD ($) director	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2016 USD ($) director	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Variable Interest Entity
Cash payments for the acquisition of certain assets of related party											$ 15,000
Charge to other expense relating to deconsolidation of DOSE								$ 25,685			25,685
Consolidation of DOSE's results of operations:
Selling, general and administrative		$ 20,494	$ 16,854	$ 15,120	$ 12,288	$ 12,392	$ 11,237	12,516	$ 7,816	$ 64,756	43,961	$ 28,135
Research and development		7,399	7,807	6,955	7,062	6,295	6,173	7,339	5,240	29,223	25,047	19,205
Net loss of DOSE		$ (134)	$ (1,159)	$ (2,332)	$ (897)	$ 2,290	$ 2,057	32,512	$ 1,462	(4,522)	38,321	14,057
Consolidation of DOSE's cash flows:
Cash used in operating activities										12,309	(2,188)	(7,107)
Cash used in investing activities										(26,116)	(85,628)	(868)
Cash provided by financing activities										(1,642)	107,110	3,500
Net (decrease) increase in cash and cash equivalents										$ (15,078)	19,268	(4,424)
DOSE Medical Corporation
Variable Interest Entity
Cash payments for the acquisition of certain assets of related party	$ 15,000
Intercompany receivable eliminated	$ 10,900							10,900
Maximum period of support under transition services agreement	3 years
Number of members of the Company’s board of directors who serve on the board of directors of DOSE | director		2								2
Charge to other expense relating to deconsolidation of DOSE								$ 25,700
DOSE Medical Corporation | Variable Interest Entity, Primary Beneficiary
Consolidation of DOSE's results of operations:
Selling, general and administrative											105	243
Research and development											890	1,557
Interest expense											85	156
Net loss of DOSE											1,080	1,956
Consolidation of DOSE's cash flows:
Cash used in operating activities											(1,134)	(1,271)
Cash used in investing activities											(33)	(39)
Cash provided by financing activities											1,158	1,315
Net (decrease) increase in cash and cash equivalents											$ (9)	$ 5